samedan logo
 
 
 
spacer
home > pmps > summer 2019 > the promise of connected health
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Promise of Connected Health

It is a known fact that measuring medication effectiveness and adherence plays an important role in managing and improving patient health. However, pharmaceutical companies struggle with procuring data that shows when, or even if, patients take their medication. A range of research has demonstrated that up to 50% of all medicines are not taken as prescribed (1). Even for patients with chronic conditions, adherence is only 50-60% (2).

These statistics are pretty eye-opening when it comes to patient health outcomes, but the news also has a negative financial impact for pharma manufacturers as medication nonadherence accounts for approximately $188 billion in lost revenue (3). Taking an even closer look, adherence rates ranging from 31-66% for popular respiratory, diabetes, and autoimmune drugs can leave between $1 billion and $10 billion ‘on the table’ in any given year (4). However, even as little as a 3% increase in adherence can generate more than $1 to $3 billion in additional revenue for these popular drugs over a five-year period. This is significant, especially as the cost of new prescription drug development can be as high as $2.6 billion (5). Despite this investment, even if patients fill their prescription, whether or not they actually take the medication cannot be guaranteed. Connected health solutions can help close this gap.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Kevin Deane is Vice President of Innovation at Phillips-Medisize. With over 25 years of experience developing new products, Kevin has supported a broad range of drug delivery and medical devices to market. He leads an early-stage development team and coordinates large-scale developments in connected health, from devices to data, pulling together the deep capabilities across Phillips-Medisize and Molex. Kevin moved from the US to Cambridge, UK, in 1994 and worked for PA Consulting as a Partner in the Technology Group. He has led a number of drug delivery and connected health projects for pharma clients across Europe, Asia Pacific, and the US, supporting strategic assessment through to full system implementations.
spacer
Kevin Deane
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo maintains its steady growth.

According to the data obtained by WACD, the international air cargo information provider, in May; Turkish Cargo, the global air cargo brand providing service to 124 countries around the world, increased its tonnage rate by 7.1 percent, and grew substantially across the industry which shrank by 5.1 percent in the global air cargo market.
More info >>

White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement